Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
28 studies found for:    Open Studies | "beta-Thalassemia"
Show Display Options
Rank Status Study
1 Recruiting Gene Therapy for Transfusion Dependent Beta-thalassemia
Condition: Beta-Thalassemia
Intervention: Genetic: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
2 Recruiting To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care
Condition: Beta-Thalassemia
Interventions: Other: Quality of Life (QOL) questionnaires;   Other: Healthcare Resource Utilization
3 Not yet recruiting A Study of EPEG in Beta Thalassemia Patients
Condition: Beta-Thalassemia
Intervention: Drug: EPEG (Pegylated erythropoeitin)
4 Recruiting A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia
Condition: Beta-Thalassemia
Intervention: Genetic: LentiGlobin BB305 Drug Product
5 Not yet recruiting An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
Condition: Beta Thalassemia Major
Intervention: Drug: Deferiprone
6 Recruiting Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
Condition: Beta-Thalassemia Major
Interventions: Drug: Basiliximab,;   Drug: cyclosporine A;   Drug: Methotrexate;   Drug: Mycophenolate mofetil
7 Recruiting Benefits of Nigella Sativa in Children With Beta Thalassemia Major
Condition: Nigella Sativa With Beta Thalassemia Major
Intervention: Drug: nigella sativ
8 Recruiting Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
Condition: Thalassemia Major
Intervention: Genetic: unrelated CB following haplo-identical hematopoietic stem cells transplantation
9 Recruiting Reproductive Capacity and Iron Burden in Thalassemia
Condition: THALASSEMIA MAJOR
Interventions: Other: Blood Draw/Semen Exam;   Other: Retrospective data/Chart Review/Relevant Clinical Results;   Other: Pituitary MRI
10 Recruiting Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major
Condition: AL-Hijama in Thalassmia Major
Interventions: Procedure: Al-hijamah;   Drug: Deferasirox
11 Recruiting An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
Conditions: Erythrocyte Transfusion;   Beta-Thalassemia
Interventions: Drug: Luspatercept;   Other: Placebo
12 Recruiting Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter
Conditions: Thalassemia;   Iron Deficiency
Intervention: Procedure: Observation of results from laboratory tests
13 Recruiting Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients
Conditions: Beta-Thalassemia;   Iron Overload
Interventions: Drug: Amlodipine;   Drug: Deferasirox
14 Not yet recruiting Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)
Conditions: Beta-thalassemia;   Serum Ferritin;   Iron Chelation Therapy
Intervention: Drug: desferal, ferriprox, blood transfusion
15 Recruiting Stem Cell Transplant in Sickle Cell Disease and Thalassemia
Conditions: Sickle Cell Disease;   Beta Thalassemia
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
16 Recruiting Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Conditions: Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
Interventions: Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Radiotherapy
17 Recruiting HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Conditions: Sickle Cell Disease;   Beta Thalassemia-Major
Interventions: Drug: alemtuzumab (Campath IH);   Drug: Fludarabine;   Drug: Melphalan;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Biological: Hematopoietic Stem Cell Transplantation
18 Recruiting B-Thalasaemia Trait and Its Possible Cardioprotective Role
Conditions: Beta-Thalassemia Trait;   Coronary Artery Disease
Intervention:
19 Recruiting The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital
Conditions: Hepatitis C;   Fibrosis;   Thalassemia
Intervention: Other: Transient elastography
20 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune )

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.